NEWS RELEASE

Expanded Access Program Launched for Viltolarsen, an Investigational Exon 53 Skipping Antisense Oligonucleotide

PARAMUS, NJ: March 9, 2020 - NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President Shigenobu Maekawa), announced the launch of the viltolarsen Expanded Access Program in the United States for patients with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 53 skipping therapy and meet other eligibility criteria.

NS Pharma has a strong commitment to the DMD community. DMD is a serious and life-threatening disease for which there are limited treatment options. This viltolarsen Expanded Access Program will allow eligible patients to receive viltolarsen while it remains an investigational drug under FDA review. Viltolarsen has not yet been approved by any regulatory authority and its safety and effectiveness has not been established. NS Pharma is pleased to launch this program and remains committed to continuing to study the efficacy and safety of viltolarsen in patients with DMD amenable to exon 53 skipping therapy.

To inquire about participation in the viltolarsen Expanded Access program, physicians must make a request on behalf of their patient to NS Pharma, where each case will be reviewed for eligibility to participate. Physicians may email nspharma.expandedaccess@earlyaccesscare.com for more information on the viltolarsen Expanded Access Program.

About Duchenne Muscular Dystrophy (DMD)
DMD is a progressive form of muscular dystrophy that occurs primarily in males. DMD causes progressive weakness and loss (atrophy) of skeletal, cardiac, and pulmonary muscles. Early signs of DMD may include delayed ability to sit, stand, or walk and difficulties learning to speak. DMD may also affect learning and memory, as well as communication and certain social emotional skills. Most children with DMD use a wheelchair full-time by age 13. Heart and respiratory muscle problems begin in the teen
years and lead to serious, life-threatening complications.

**About Viltolarsen**
Viltolarsen has been granted a Rare Pediatric Disease Designation, Orphan Drug Designation, and a Fast Track Designation in the U.S., and "SAKIGAKE designation", "Orphan drug designation", and designation of Conditional Early Approval System in Japan.

**About NS Pharma, Inc.**
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit [http://www.nspharma.com](http://www.nspharma.com). NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

Contact
U.S. Media Contact:

[media@nspharma.com](mailto:media@nspharma.com)